Palisade Bio, Inc. (PALI) NASDAQ
1.93
-0.02(-1.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.93
-0.02(-1.03%)
Currency In USD
| Previous Close | 1.95 |
| Open | 1.95 |
| Day High | 2 |
| Day Low | 1.92 |
| 52-Week High | 2.86 |
| 52-Week Low | 0.53 |
| Volume | 2.18M |
| Average Volume | 4.03M |
| Market Cap | 323.12M |
| PE | -6.43 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.94 |
| Moving Average 200 Days | 1.59 |
| Change | -0.02 |
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
GlobeNewswire Inc.
Mar 02, 2026 2:00 PM GMT
Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
GlobeNewswire Inc.
Feb 23, 2026 1:40 PM GMT
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiat
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
GlobeNewswire Inc.
Feb 17, 2026 1:45 PM GMT
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pal